HomeCompareDBIN vs PFE

DBIN vs PFE: Dividend Comparison 2026

DBIN yields 1.60% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $24.6K in total portfolio value· pulled ahead in Year 9
10 years
DBIN
DBIN
● Live price
1.60%
Share price
$42.50
Annual div
$0.68
5Y div CAGR
14.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.9K
Annual income
$773.85
Full DBIN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DBIN vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDBINPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DBIN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DBIN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DBIN
Annual income on $10K today (after 15% tax)
$136.00/yr
After 10yr DRIP, annual income (after tax)
$657.77/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,662.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DBIN + PFE for your $10,000?

DBIN: 50%PFE: 50%
100% PFE50/50100% DBIN
Portfolio after 10yr
$37.2K
Annual income
$13,516.28/yr
Blended yield
36.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DBIN
No analyst data
Altman Z
0.3
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DBIN buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDBINPFE
Forward yield1.60%6.13%
Annual dividend / share$0.68$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR14.7%13.2%
Portfolio after 10y$24.9K$49.6K
Annual income after 10y$773.85$26,258.71
Total dividends collected$4.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DBIN vs PFE ($10,000, DRIP)

YearDBIN PortfolioDBIN Income/yrPFE PortfolioPFE Income/yrGap
1$10,884$183.52$9,153$693.39+$1.7KDBIN
2$11,859$214.11$8,593$849.25+$3.3KDBIN
3$12,940$250.10$8,336$1,066.78+$4.6KDBIN
4$14,138$292.51$8,437$1,384.80+$5.7KDBIN
5$15,470$342.60$9,013$1,875.40+$6.5KDBIN
6$16,955$401.87$10,306$2,680.72+$6.6KDBIN
7$18,614$472.13$12,820$4,101.38+$5.8KDBIN
8$20,473$555.63$17,673$6,826.70+$2.8KDBIN
9← crossover$22,561$655.08$27,543$12,591.86$5.0KPFE
10$24,914$773.85$49,560$26,258.71$24.6KPFE

DBIN vs PFE: Complete Analysis 2026

DBINStock

Dacotah Banks, Inc. operates as the bank holding company for Dacotah Bank that provides various banking services to individuals and businesses. The company accepts demand and certificates of deposit; and checking, individual retirement, and money market accounts. It also offers vehicle, boat, motorhome, mortgage, camper, motorcycle, snowmobile, jet SKI, and ATV loans; and unsecured, overdraft protection, and student loans. In addition, the company provides credit, debit, and gift cards; and personal insurance, personal investment, wealth management, estate, and trust services. Further, it offers retirement planning, investment management, foundation, endowment, bill paying, and elder care services, as well as cash management and merchant solutions. Additionally, the company provides line of credit, small business administration loans, term loans, and leasing services, as well as estate planning and estate settlement services. Furthermore, the company offers operating lines of credit, real estate loans, and equipment loans and leases. The company provides crop, homeowner, health, life, farm, and ranch insurance services. The company operates through 32 branches in South Dakota, North Dakota, and Minnesota. Dacotah Banks, Inc. was founded in 1964 and is headquartered in Aberdeen, South Dakota.

Full DBIN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DBIN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DBIN vs SCHDDBIN vs JEPIDBIN vs ODBIN vs KODBIN vs MAINDBIN vs JNJDBIN vs MRKDBIN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.